TEST:

CancerSCAN

Five-year breast cancer risk calculated with BOADICEA indicates that there is a wide distribution of risk within the dense population. In a cohort of 8353 women participating in a supplemental imaging study, cancers diagnosed were overrepresented in the fourth quartile of risk suggesting that risk may be used to better discriminate those who would benefit from enhanced screening.Within a cohort with dense breast tissue, risk calculated from participant-completed questionnaires is shown to partially predict cancer diagnosis from initial data with a median follow-up time of 20 months.

This study showed the potential of AI deep learning and machine learning pipeline that employs an innovate prognostic genetic markers for HER2-negative AGC. Current ongoing analyses of larger cohort with more comprehensive clinical data will be presented.

Cervix samples might be a non-invasive diagnostic method for ovarian cancer. Further research and validation are warranted to confirm these findings.

NGS can provide information about predictive biomarkers and drug-targetable biomarkers that can enable treatment and participation in clinical trials based on precision medicine. Further studies should be conducted to excavate novel drug-targetable biomarkers and develop additional target therapies.

"Based on the EGFR genotyping by ADPS, the treatment options could be switched in five patients. The highly sensitive and specific ADPS™ EGFR Mutation Test Kit would be useful in detecting the patients who have lung cancer with EGFR mutation, and can benefit from the EGFR targeted therapy."